Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says
August 15, 2022 at 02:42 AM EDT
AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial.
